Oxford Biomedica Solutions
Vincent Leonard Thari currently serves as Research Associate II at Oxford Biomedica since January 2023. Prior experience includes roles as a Graduate Student and Graduate Research Assistant at Carnegie Mellon University from August 2021 to December 2022. Earlier, Vincent completed an undergraduate degree at GITAM Deemed University between June 2016 and June 2020, where an internship at Virchow Biotech in May 2019 provided exposure to GMP techniques in manufacturing. Vincent earned a Master's degree in Biotechnology and Pharmaceutical Engineering from Carnegie Mellon University in December 2022.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.